FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1400 November 5, 1998 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Imura, H. Related Article by Salama, A. D. PubMed Citation

To the Editor: Troglitazone is an antidiabetic drug that decreases hyperglycemia by increasing the sensitivity of peripheral tissue to insulin.¹ Its most serious adverse effect is hepatic dysfunction, which occurs in a small percentage of patients.² We describe a case of pleuritis in a patient who was treated with troglitazone.

The patient was a 47-year-old man who had been treated for hypertension and type 2 diabetes mellitus with slow-release nifedipine and glyburide, respectively. He had smoked 1 1/2 packs of cigarettes daily for 18 years but had stopped 10 years earlier. He had no history of drug allergy or occupational . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kunzi, T., Walther, F., Marti, H.-P., Frey, F. J., Vogt, B. (2005). Intrarenal arterial aneurysms with haematuria in a patient with tuberous sclerosis complex. Nephrol Dial Transplant 20: 2268-2270 [Full Text]  
• Aleo, M. D., Lundeen, G. R., Blackwell, D. K., Smith, W. M., Coleman, G. L., Stadnicki, S. W., Kluwe, W. M. (2003). Mechanism and Implications of Brown Adipose Tissue Proliferation in Rats and Monkeys Treated with the Thiazolidinedione Darglitazone, a Potent Peroxisome Proliferator-Activated Receptor-{gamma} Agonist. J. Pharmacol. Exp. Ther. 305: 1173-1182 [Abstract] [Full Text]